Institut de Recherches Internationales Servier
servier.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
72
Active
15
Phase 3
18
Total enrollment
46,082
Pipeline matrix
Showing 34 of 34 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vorasidenib | — | — | — | 7 | |||
| AG-120 | — | — | — | — | 6 | ||
| Ivosidenib | — | — | — | — | 2 | ||
| Azacitidine | — | — | — | — | — | 2 | |
| Trifluridine/tipiracil hydrochloride | — | — | — | — | 3 | ||
| Capecitabine | — | — | — | — | — | 1 | |
| Bevacizumab experimental | — | — | — | — | — | 1 | |
| Bevacizumab control | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | 3 | ||
| Nab-paclitaxel | — | — | — | — | 2 | ||
| Durvalumab | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Ivosidenib Recommended Combination Dose | — | — | — | — | — | 1 | |
| BN104 monotherapy | — | — | — | — | — | 1 | |
| BN104 monotherapy - rp2d | — | — | — | — | — | 1 | |
| S241656 | — | — | — | — | — | 1 | |
| FOLFOX6/FOLFOX7 | — | — | — | — | — | 1 | |
| FOLFIRI | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | — | — | 1 | |
| Panitumumab | — | — | — | — | — | 1 | |
| S230815- Starting dose A | — | — | — | — | — | 1 | |
| S230815- Dose B | — | — | — | — | — | 1 | |
| S230815- Dose C | — | — | — | — | — | 1 | |
| S230815- Dose D | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Vorasidenib 20mg | — | — | — | — | — | 1 | |
| AG-221 | — | — | — | — | — | 1 | |
| cytarabine | — | — | — | — | — | 1 | |
| daunorubicin | — | — | — | — | — | 1 | |
| idarubicin | — | — | — | — | — | 1 | |
| mitoxantrone | — | — | — | — | — | 1 | |
| etoposide | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| UCART19 follow-up | — | — | — | — | — | 1 |
Next readouts
- 2018-12-13
- 2021-03-18
- 2021-06-29
- 2022-09-06
- 2026-02-12
- 2026-07-23
- 2026-11-23
- 2026-12
- 2026-12-31
- 2027-11
Top conditions
- Metastatic Colorectal Cancer6
- Hypertension4
- Acute Lymphoblastic Leukemia4
- Untreated AML3
- Glioma3
- Autism Spectrum Disorder (ASD)2
- Acute Myeloid Leukaemia (AML)2
- Myelodysplastic Syndrome (MDS)2
Frequently asked questions about Institut de Recherches Internationales Servier
- How many clinical trials does Institut de Recherches Internationales Servier have on ClinicalTrials.gov?
- Institut de Recherches Internationales Servier is listed as the lead sponsor on 72 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut de Recherches Internationales Servier's trials are in Phase 3?
- 18 of Institut de Recherches Internationales Servier's trials are in Phase 3, spread across 34 active drug programs.
- What therapeutic areas does Institut de Recherches Internationales Servier focus on?
- Institut de Recherches Internationales Servier's most-studied conditions on ClinicalTrials.gov are Metastatic Colorectal Cancer, Hypertension, Acute Lymphoblastic Leukemia, Untreated AML, Glioma.
- When are Institut de Recherches Internationales Servier's next clinical trial readouts?
- Institut de Recherches Internationales Servier has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation”, expected around 2018-12-13.